Source · Prevention of Future Deaths
Patricia Mellor
Ref: 2014-0491
Date: 12 Nov 2014
Coroner: Jane Gillespie
Area: Nottinghamshire
Responses identified: 0 / 4
View PDF
Despite detailed recommendations from a hospital regarding Long QT Syndrome and drug-related cardiac arrest risks during anaesthesia, regulatory bodies (MHRA, NICE) have failed to update guidelines and product warnings.
Date
12 Nov 2014
56-day deadline
7 Jan 2015
Responses identified
0 of 4
Coroner's concerns
Despite detailed recommendations from a hospital regarding Long QT Syndrome and drug-related cardiac arrest risks during anaesthesia, regulatory bodies (MHRA, NICE) have failed to update guidelines and product warnings.
View full coroner's concerns
Consultant Anaesthetist has advised that in response to this incident, the Derby Hospitals NHS Trust undertook the following action;
· All 12 lead ECG devices were programmed to print a “Long QTc” warning when detected
· An educational programme on LQTS was delivered to all Anaesthetists working in the Trust
· A protocol was developed to require a pre-operative ECG for all patients taking drugs listed on the expert database at “high” and “intermediate” risk levels of causing cardiac arrest – this overrides the advice in the NICE CG3 document
· When a prolonged QTc is discovered; o The patient is questioned about cardiac arrest or sudden unexpected death in a young family member; if this is discovered, the patient is referred to a cardiologist to exclude Congenital LQTS
o The patient has plasma electrolyte levels (specifically potassium, magnesium and calcium) measured irrespective of any contrary advice in the NICE CG3 guideline. Any abnormal low level is treated before surgery
· The Anaesthetist for the relevant operating list is alerted to any abnormal QTc finding
· A protocol was developed to; (1) guide the safe administration of general anaesthesia to patients with LQTS, and (2) guide the optimum management of cardiac arrest if this occurs under anaesthesia
· Investment was provided for electronic pumps to allow the ready availability of TIVA
further advised that the likelihood of this event being due to a drug-related phenomenon was reported to the Medicines and Healthcare Products Regulatory Agency (MHRA) using the “yellow card” scheme.
There were further communications with the MHRA suggesting that;
· The product information for inhalational anaesthetic agents should contain a warning on the potential risks of cardiac arrest when administered to patients with LQTS
· The product information for other drugs such as 5HT3 anti-emetics should contain a warning on the potential risks of cardiac arrest when administered to patients with LQTS during inhalational anaesthesia
· The particular issues with antidepressant agents and LQTS should be highlighted in the regular bulletins from the Agency
Furthermore, reported that recommendations be sent to NICE updating guideline CG3 to;
· Instruct anaesthetists to consider drug-induced LQTS in their pre-operative assessment before following the recommendation not to perform a 12 lead ECG
· Instruct anaesthetists to specifically examine the QTc interval in all pre-operative ECGs performed for any indication
· To require a 12 lead ECG to be recorded and the QTC to be specifically examined in all patients receiving agents deemed to be of “high” and “intermediate” risk of inducing cardiac arrest in LQTS
advised that despite the above notifications and recommendations, no action has been taken by these agencies.
· All 12 lead ECG devices were programmed to print a “Long QTc” warning when detected
· An educational programme on LQTS was delivered to all Anaesthetists working in the Trust
· A protocol was developed to require a pre-operative ECG for all patients taking drugs listed on the expert database at “high” and “intermediate” risk levels of causing cardiac arrest – this overrides the advice in the NICE CG3 document
· When a prolonged QTc is discovered; o The patient is questioned about cardiac arrest or sudden unexpected death in a young family member; if this is discovered, the patient is referred to a cardiologist to exclude Congenital LQTS
o The patient has plasma electrolyte levels (specifically potassium, magnesium and calcium) measured irrespective of any contrary advice in the NICE CG3 guideline. Any abnormal low level is treated before surgery
· The Anaesthetist for the relevant operating list is alerted to any abnormal QTc finding
· A protocol was developed to; (1) guide the safe administration of general anaesthesia to patients with LQTS, and (2) guide the optimum management of cardiac arrest if this occurs under anaesthesia
· Investment was provided for electronic pumps to allow the ready availability of TIVA
further advised that the likelihood of this event being due to a drug-related phenomenon was reported to the Medicines and Healthcare Products Regulatory Agency (MHRA) using the “yellow card” scheme.
There were further communications with the MHRA suggesting that;
· The product information for inhalational anaesthetic agents should contain a warning on the potential risks of cardiac arrest when administered to patients with LQTS
· The product information for other drugs such as 5HT3 anti-emetics should contain a warning on the potential risks of cardiac arrest when administered to patients with LQTS during inhalational anaesthesia
· The particular issues with antidepressant agents and LQTS should be highlighted in the regular bulletins from the Agency
Furthermore, reported that recommendations be sent to NICE updating guideline CG3 to;
· Instruct anaesthetists to consider drug-induced LQTS in their pre-operative assessment before following the recommendation not to perform a 12 lead ECG
· Instruct anaesthetists to specifically examine the QTc interval in all pre-operative ECGs performed for any indication
· To require a 12 lead ECG to be recorded and the QTC to be specifically examined in all patients receiving agents deemed to be of “high” and “intermediate” risk of inducing cardiac arrest in LQTS
advised that despite the above notifications and recommendations, no action has been taken by these agencies.
Report sections
Investigation and inquest
On 29th January 2014 I commenced an investigation into the death of Patricia Ann Mellor, aged 63. The investigation concluded at the end of the inquest on 7th October 2014. The conclusion of the inquest was:
On the 24th day of January 2014 Patricia Ann Mellor died as a result of aspiration pneumonia. This was a direct result of the hypoxic brain injury that she suffered following a cardiac arrest during surgery in 2004. The cardiac arrest during general anaesthesia was a consequence of a phenomenon known as acquired Long QT Syndrome, due to a combination of citalopram, nortriptyline and ranitidine therapies. This reaction could not have been predicted in 2004.
On the 24th day of January 2014 Patricia Ann Mellor died as a result of aspiration pneumonia. This was a direct result of the hypoxic brain injury that she suffered following a cardiac arrest during surgery in 2004. The cardiac arrest during general anaesthesia was a consequence of a phenomenon known as acquired Long QT Syndrome, due to a combination of citalopram, nortriptyline and ranitidine therapies. This reaction could not have been predicted in 2004.
Circumstances of the death
On 30.03.04 Mrs Mellor underwent an arthroscopic examination of her left temporomandibular joint for chronic pain in this area. Mrs Mellor was subject to a thorough assessment by Consultant Anaesthetist, on the morning of her surgery. had some concerns regarding the placement of a breathing pipe necessary for the operation given Mrs Mellor’s difficulty in opening her jaw and her significant reflux disease. She had also previously experienced severe post-anaesthetic nausea and vomiting and episodes of hypertension during general anaesthetic. was confident that these risks could be managed and the general anaesthetic went ahead, in preparation for the operation which was to be performed by Consultant Maxillofacial Surgeon. Very shortly into the operation, before any incision was made, Mrs Mellor became hypertensive, did not respond to the usual medications and went into cardiac arrest. Resuscitation was commenced and continued for 20 minutes before spontaneous circulation was re-established. When Mrs Mellor’s was taken off sedation she was found to have a hypoxic brain injury. Since that time she has been severely disabled and fully dependent on others for her care and health needs. On 24th January 2014 she died as a result of aspiration pneumonia, 10 years after suffering her hypoxic brain injury. Following this event, a full investigation was carried out to try to establish the cause of her cardiac arrest. Anaphylactic shock, abnormal heart valve/s and abnormalities in the heart muscle were all excluded. It was concluded that Mrs Mellor had acquired Long QT Syndrome, from the combination of citalopram, nortriptyline and ranitidine therapies. It was considered that this caused a reaction to general anaesthesia, which in turn provoked the Long QT Syndrome, leading to cardiac arrest.
Long QT syndrome (LQTS) is a disorder of the heart's electrical activity. The term "long QT" refers to an abnormal pattern seen on an electrocardiogram. It can cause sudden, uncontrollable, dangerous arrhythmias. This may be an inherited naturally occurring condition or it may be acquired. Acquired LQTS can be caused by certain medication/combinations of certain medications.
Long QT syndrome (LQTS) is a disorder of the heart's electrical activity. The term "long QT" refers to an abnormal pattern seen on an electrocardiogram. It can cause sudden, uncontrollable, dangerous arrhythmias. This may be an inherited naturally occurring condition or it may be acquired. Acquired LQTS can be caused by certain medication/combinations of certain medications.
Action should be taken
I require you to provide an explanation and reasons regarding;
(i) the decision taken not to respond to the recommendations set out above (ii) whether this decision will be reviewed in light of this report (iii) if no action is to be taken in light of this report, the reasons for this (iv) if action is to be taken, what that action will be and the timescales for such
(i) the decision taken not to respond to the recommendations set out above (ii) whether this decision will be reviewed in light of this report (iii) if no action is to be taken in light of this report, the reasons for this (iv) if action is to be taken, what that action will be and the timescales for such
Similar PFD reports
Related inquiry recommendations
Scottish Hospitals Inquiry
Training for IPC professionals engineers and clinicians
Scottish Hospitals Inquiry
IPC role specifications and staffing levels
Southport Inquiry
Autism spectrum disorder police training
Southport Inquiry
Prevent training on online activity assessment
Southport Inquiry
Neurodiversity training for Prevent practitioners
Southport Inquiry
Balancing vulnerability with professional curiosity
Southport Inquiry
Sharing information about closed Prevent referrals
Southport Inquiry
Prevent Supervisor training on closure decisions
Southport Inquiry
Prevent referral training for organisations
Southport Inquiry
Taxi driver duty to report criminal activity
Report details
- Reference
- 2014-0491
- Date of report
- 12 November 2014
- Coroner
- Jane Gillespie
- Coroner area
- Nottinghamshire
Responses identified
Responses identified
0 of 4
4 responses not yet linked
Organisations named in PFD reports are normally expected to respond within 56 days. Deadline: 7 Jan 2015.
Sent to
- Derby Hospitals NHS Foundation Trust
- Medicines and Healthcare Product Regulatory Agency
- National Institute for Health and Care Excellence
- National Patient Safety Agency